Panel Therapeutic Insights track
ADCs in oncology: What does the data show?
Mon, Nov 9, 2026 · 2:00–2:45 PM CET Therapeutic Insights Stage, Koelnmesse
About this session
Antibody-drug conjugates (ADCs) are transforming cancer treatment by delivering targeted therapy with precision, and as clinical data matures, they are attracting significant investment and partnership activity across the oncology landscape. This session examines the latest evidence on efficacy and safety, explores what the data reveals about how ADCs are reshaping treatment strategies across tumour types, and discusses which platforms and targets are capturing attention from investors and partners.
